Alveus Therapeutics emerged with a $159.8 million Series A to advance an obesity program designed to mirror tirzepatide’s multimodal efficacy with potential dosing advantages. The company’s Phase‑2 ready lead and pipeline intend to compete in GLP‑1/GIP and amylin‑targeted spaces, positioning Alveus to run head‑to‑head studies as the obesity drug market evolves. Investors cited the need for next‑gen molecules that improve tolerability and long‑term maintenance. Alveus said the funds will be used to complete phase 2 development and expand manufacturing and regulatory activities ahead of late‑stage trials.